← Back to patent-cliff list
Rifabutin (BioVersys)
Tier C — Watch / tradeRifabutin (BioVersys)
BioVersys AG
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：RNAP
Indications (approved)：鲍曼不动杆菌感染, Ventilator-associated pneumonia, Hospital-acquired pneumonia, 脑室炎, Bacterial infection, 细菌性脑膜炎, Renal impairment
Regional status
US
-
EU
Phase I
2020-11-09
China
Phase I
2025-11-03
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Rifabutin (BioVersys)?
Approved indications include: 鲍曼不动杆菌感染, Ventilator-associated pneumonia, Hospital-acquired pneumonia, 脑室炎, Bacterial infection, 细菌性脑膜炎, Renal impairment.
When does the Rifabutin (BioVersys) patent expire?
No public expiry year is available for Rifabutin (BioVersys) yet; this page updates once verified.
How do I get a quote for Rifabutin (BioVersys) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29